Does BCR-ABL genomic rearrangement persist in CML patients in complete remission after interferon α therapy?

Leukemia

Volumn 12, Issue 7, 1998, Pages 1076-1080

  Brizard, F ^a   Chomel, J C ^a   Veinstein, A ^a   Rivet, J ^a   Giraud, C ^a   Kitzis, A ^a   Guilhot, F ^a   Brizard, A ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

BCR ABL; FISH; Interferon ; Leukapheresis; Minimal residual disease; RT PCR

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; HYDROXYUREA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; PERIPHERAL BLOOD STEM CELL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0031854819     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401053     Document Type: Article

References (26)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497-1501.
2. Rowley JD. A new consistent chromosome abnormality in chronic myelogenous leukemia detected by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293.
3. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36: 93-99.
4. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature 1985; 315: 550-554.
5. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, Bouabdallah R, Guiotat D, Cheron N, Nicolini F, Abgrall JF, Tanzer J for the French Chronic myeloid Leukemia Study Group. Interferon alpha-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. New Engl J Med 1997; 337: 223-229.
6. Lion T, Gaiger A, Izraeli S, Henn T, Mor W, Gadner H. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction. Leukemia 1992; 6: 495-499.
7. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, Shepard PCA, Allan NA, Hehlmann R, Goldman JM, Cross CP. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-α therapy by competitive polymerase chain reaction. Blood 1996; 87: 1549-1555.
8. Bhatia R, Verfaillie CM, Miller JS, McGlave PB. Autologous transplantation therapy for chronic myelogenous leukemia. Blood 1997; 89: 2623-2634.
9. Carreras E, Sierra J, Rovira M, Urbano-Ispizua A, Martinez C, Nomdedeu B, Cervantes F, Marin P, Rozman C, Montserrat E. Successful autografting in chronic myelogenous leukaemia using Philadelphia negative blood progenitor cells mobilized with rHuG-CSF alone in a patient responding to alpha-interferon. Br J Haematol 1997; 96: 421-423.
10. Tkachuk DC, Westbrook CA, Andreeff M, Donlon TA, Cleary ML, Suzyanarayan K, Homhe M, Redner A, Gray J, Pinkel D. Detection of bcr-abl fusion in chronic myelogenous leukemia by in situ hybridization. Science 1990; 250: 559-562.
11. Chase A, Grand F, Zhang J-G, Blackett N, Goldman J, Gordon M. Factors influencing the false positive and negative rates of BCR-ABL fluorescence in situ hybridization. Genes Chromosom Cancer 1997; 18: 246-253.
12. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
13. Cross NCR, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929-1936.
14. lo population in chronic myeloid leukemia: an analysis using interphase fluorescence in situ hybridization. Blood 1995; 86: 737-743.
15. Verfaillie CM, Bhatia R, Miller W, Mortari F, Roy V, Burger S, McCullough J, Stieglbauer K, Dewald G, Heimfeld S, Miller JS, McGlave PB. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients. Blood 1996; 87: 4770-4779.
16. Sinclair PB, Green AR, Grace C, Nacheva EP. Improved sensitivity of BCR-ABL detection: a triple-probe three-color fluorescence in situ hybridization system. Blood 1997; 90: 1395-1402.
17. Bedi A, Zehnbauer BA, Collector MI, Barber JP, Zicha MS, Sharkis SJ, Jones RJ. BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. Blood 1993; 81: 2898-2902.
18. Leemhuis T, Leibowitz D, Cox G, Silver R, Srour EF, Tricor G, Hoffman R. Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow. Blood 1993; 81: 801-807.
19. Keating A, Wang XH, Laraya P. Variable transcription of BCR-ABL by Ph+ cells arising from hematopoietic progenitors in chronic myeloid leukemia. Blood 1994; 83: 1744-1749.
20. Yin JL, Williams BG, Arthur CK, Ma DDF. Interferon response in chronic myeloid leukaemia correlated with ABL/BCR expression: a preliminary study. Br J Haematol 1995; 89: 539-545.
21. El-Rifai W, Ruutu T, Vettenranta K, Temtamy S, Knuutila S. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia: a metaphase-FISH study. Br J Haematol 1996; 92: 365-369.
22. Maguer-Satta V, Petzer AL, Eaves AC, Eaves CJ. BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia. Blood 1996; 88: 1796-1804.
23. Zhang JG, Lin F, Chase A, Goldman JM, Cross NCP. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation. Blood 1996; 87: 2588-2593.
24. Lengyel P. Tumor-suppressor genes: news about the interferon connection. Proc Natl Acad Sci USA 1993; 90: 5893-5895.
25. Shirodkar S, Ewen M, De Caprio JA, Morgan J, Livingston DM, Chittenden T. The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner. Cell 1992; 68: 157-166.
26. Furukawa Y, Iwase S. Antileukemic effect of interferon-α is mediated through down-modulation of E2F activity. Leukemia 1997; 11: 446-448.